Cara Therapeutics Discontinues NP Program After Drug Study Fails to Show Clinical Benefit -- Shares Drop

MT Newswires Live06-13

Cara Therapeutics (CARA) said late Wednesday the results of a trial assessing the efficacy and safety of oral difelikefalin to treat notalgia paresthetica, a nerve disorder, didn't demonstrate meaningful clinical benefit compared to placebo.

The company has decided to discontinue its clinical program in notalgia paresthetica.

"We will be winding down the Phase 2/3 clinical program in [notalgia paresthetica] and exploring strategic alternatives focused on maximizing shareholder value," said Cara Chief Executive Christopher Posner.

The company said, as of March 31, it had about $70 million in cash, cash equivalents, and marketable securities.

Cara shares were down more than 15% in after-hours activity.

Price: 0.5761, Change: -0.10, Percent Change: -15.22

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2443944395?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-13 04:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2443944395","market":"nz","top_or_hot":-1,"title":"Cara Therapeutics Discontinues NP Program After Drug Study Fails to Show Clinical Benefit -- Shares Drop","media":"MT Newswires Live","content":"<html><body><p> Cara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CARA) said late Wednesday the results of a trial assessing the efficacy and safety of oral difelikefalin to treat notalgia paresthetica, a nerve disorder, didn't demonstrate meaningful clinical benefit compared to placebo.</p><p>The company has decided to discontinue its clinical program in notalgia paresthetica.</p><p>\"We will be winding down the Phase 2/3 clinical program in [notalgia paresthetica] and exploring strategic alternatives focused on maximizing shareholder value,\" said Cara Chief Executive Christopher Posner.</p><p>The company said, as of March 31, it had about $70 million in cash, cash equivalents, and marketable securities.</p><p>Cara shares were down more than 15% in after-hours activity.</p><p>Price: 0.5761, Change: -0.10, Percent Change: -15.22</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cara Therapeutics Discontinues NP Program After Drug Study Fails to Show Clinical Benefit -- Shares Drop</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCara Therapeutics Discontinues NP Program After Drug Study Fails to Show Clinical Benefit -- Shares Drop\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-13 04:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cara Therapeutics (CARA) said late Wednesday the results of a trial assessing the efficacy and safety of oral difelikefalin to treat notalgia paresthetica, a nerve disorder, didn't demonstrate ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CARA","symbol_name":"Cara Therapeutics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2443944395","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2443944395","pubTimestamp":1718223800,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cara Therapeutics  said late Wednesday the results of a trial assessing the efficacy and safety of oral difelikefalin to treat notalgia paresthetica, a nerve disorder, didn't demonstrate meaningful clinical benefit compared to placebo.The company has decided to discontinue its clinical program in notalgia paresthetica.\"We will be winding down the Phase 2/3 clinical program in [notalgia paresthetica] and exploring strategic alternatives focused on maximizing shareholder value,\" said Cara Chief Executive Christopher Posner.The company said, as of March 31, it had about $70 million in cash, cash equivalents, and marketable securities.Cara shares were down more than 15% in after-hours activity.Price: 0.5761, Change: -0.10, Percent Change: -15.22","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CARA":"Cara Therapeutics, Inc.","BK4007":"制药"},"translate_title":"Cara Therapeutics因药物研究未能显示临床益处而终止NP项目——股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CARA":1},"content_text":"Cara Therapeutics (CARA) said late Wednesday the results of a trial assessing the efficacy and safety of oral difelikefalin to treat notalgia paresthetica, a nerve disorder, didn't demonstrate meaningful clinical benefit compared to placebo.The company has decided to discontinue its clinical program in notalgia paresthetica.\"We will be winding down the Phase 2/3 clinical program in [notalgia paresthetica] and exploring strategic alternatives focused on maximizing shareholder value,\" said Cara Chief Executive Christopher Posner.The company said, as of March 31, it had about $70 million in cash, cash equivalents, and marketable securities.Cara shares were down more than 15% in after-hours activity.Price: 0.5761, Change: -0.10, Percent Change: -15.22","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2443944395"}